| Serial Number | 90481364 |
| Word Mark | T |
| Filing Date | Friday, January 22, 2021 |
| Status | 604 - ABANDONED - AFTER INTER-PARTES DECISION |
| Status Date | Saturday, July 9, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, September 7, 2021 |
| Description of Mark | The mark consists of a capitalized letter "T" in stylized form. |
| Goods and Services | Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical assay kits comprised of diagnostic reagents and assays for medical use; Diagnostic kits comprised of medical immunosequencing-based diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing assay kits comprised of diagnostic reagents and assays for medical use; Medical immunosequencing-based assay kits comprised of medical grade reagents and sample plates for detecting cancer, autoimmune disease and infection |
| Goods and Services | Providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical analysis services for diagnostic and prognostic testing and treatment purposes; providing medical diagnostic and prognostic testing services; providing medical immunosequencing-based testing for cancer, autoimmune disease and infection; consulting services in the field of medical immunosequencing-based testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services relating to the diagnosis and treatment of person |
| Goods and Services | Providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapy, oncology, hematology, auto-immune disorders, and infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; medical laboratory immunosequencing-based services for analysis of biological samples |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 8 - Abandoned |
| Class Status Date | Saturday, July 9, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 8 - Abandoned |
| Class Status Date | Saturday, July 9, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 8 - Abandoned |
| Class Status Date | Saturday, July 9, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Adaptive Biotechnologies Corp. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Seattle, WA 98102 |
| Party Name | Adaptive Biotechnologies Corp. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Seattle, WA 98102 |
| Event Date | Event Description |
| Monday, July 11, 2022 | ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION |
| Saturday, July 9, 2022 | ABANDONMENT - AFTER INTER PARTES DECISION |
| Saturday, July 9, 2022 | OPPOSITION TERMINATED NO. 999999 |
| Saturday, July 9, 2022 | OPPOSITION SUSTAINED NO. 999999 |
| Wednesday, November 24, 2021 | OPPOSITION INSTITUTED NO. 999999 |
| Wednesday, September 15, 2021 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, September 7, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 7, 2021 | PUBLISHED FOR OPPOSITION |
| Wednesday, August 18, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, August 2, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, July 28, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, July 28, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, July 28, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, July 28, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, July 20, 2021 | ASSIGNED TO EXAMINER |
| Friday, April 23, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, January 26, 2021 | NEW APPLICATION ENTERED IN TRAM |